CLASS II Drug recall · Reported 20 Jun 2012 · FDA Enforcement Report

Octreotide Acetate Injection, 50 mcg/mL 05 mg/mL) single dose vials recalled

Ben Venue Laboratories is recalling Octreotide Acetate Injection, 50 mcg/mL 05 mg/mL) single dose vials, distributed nationwide in the US. The recall was initiated on 1 May 2012 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot # 2006500, Exp 08/31/12
Quantity recalled6,515 packs

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1377-2012
FDA event ID
61802
Recalling firm
Ben Venue Laboratories, Bedford, OH
Classification
Class II
Status
Terminated
Recall initiated
1 May 2012
FDA classified
14 Jun 2012
Reported
20 Jun 2012
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Packaging Defects

Timeline

1 May 2012Recall initiated by company
14 Jun 2012Classified by FDA+44 days
20 Jun 2012Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Short Fill: These products are being recalled because there is potential that vials with low fill volume were released into distribution.

Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.

Product as listed by the FDA

Octreotide Acetate Injection, 50 mcg/mL (0.05 mg/mL), 1 mL single dose vials, packaged in 10 x 1 mL single dose vials per pack, Rx only, Manufactured for: Bedford Laboratories, Bedford, OH 44146; Manufactured by: Ben Venue Laboratories, Inc., Bedford, OH 44146; NDC 55390-160-10; UPC 3 55390-160-10 1.

Where it was distributed

Nationwide and Puerto Rico.

Nationwide Puerto Rico

Questions about this recall

Is Octreotide Acetate Injection, 50 mcg/mL 05 mg/mL) single dose vials recalled?

Yes. Ben Venue Laboratories recalled Octreotide Acetate Injection, 50 mcg/mL 05 mg/mL) single dose vials on 1 May 2012. The recall is Class II and its status is Terminated. Recall number D-1377-2012.

Why was it recalled?

Short Fill: These products are being recalled because there is potential that vials with low fill volume were released into distribution.

Which lots are affected?

Lot # 2006500, Exp 08/31/12

Where was it sold?

Nationwide and Puerto Rico.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Ben Venue Laboratories

All 6

Other Octreotide recalls

All 11
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIOctreotide Acetate for Injectable Suspension recalledOctreotide AcetateTeva Pharmaceuticals USASterilityNationwide
DrugCLASS IIOctreotide Acetate for Injectable Suspension recalledOctreotide AcetateTeva Pharmaceuticals USASterilityNationwide
DrugCLASS IIOctreotide Acetate for Injectable Suspension recalledOctreotide AcetateTeva Pharmaceuticals USASterilityNationwide
DrugCLASS IIOctreotide Acetate for Injectable Suspension recalledOctreotide AcetateTeva Pharmaceuticals USASterilityNationwide
DrugCLASS IOctreotide Acetate Injection 500 mcg/mL recalled by ViatrisOctreotide AcetateViatrisParticulate MatterNationwide